# Solving safety data complexity is not an AI quick-fix

- Articles, Resources  
- February 23, 2026

European Pharmaceutical Manufacturer spotlights Daniel O’Keeffe of Qinecsa Solutions in a recent article examining whether patient outcomes are being compromised by fragmented and inconsistent safety data. Daniel highlights the critical need to improve how adverse event data is captured at source, arguing that AI’s greatest value lies in enabling better data collection rather than fixing poor-quality inputs later. He also explores how stronger regulatory direction and more structured reporting approaches could help the industry unlock clearer safety insights and ultimately drive better patient outcomes.

[Read article](https://pharmaceuticalmanufacturer.media/pharmaceutical-industry-insights/digital-health-in-pharma/solving-safety-data-complexity-is-not-an-ai-quick-fix/)

## Recent Articles

### [The Productivity Crisis That Persists Even Now: What Will It Take to Free Up PV Professionals to Assess Safety, Rather Than Coordinate Data?](/content/resources/the-productivity-crisis-that-persists-even-now-what-will-it-take-to-free-up-pv-professionals-to-assess-safety-rather-than-coordinate-data/index.html)

- July 28, 2026

### [Embracing quantitative signal detection methods as a smaller MAH](/content/resources/embracing-quantitative-signal-detection-methods-as-a-smaller-mah/index.html)

- June 25, 2026

### [Real-Time Safety Signals Drive Continuous PV Insight](/content/articles/real-time-safety-signals-drive-continuous-pv-insight/index.html)

- May 27, 2026

### [From Complaint Handling to Active Surveillance](/content/resources/from-complaint-handling-to-active-surveillance/index.html)

- May 5, 2026

### [Continuous Safety Surveillance for Medical Devices](/content/resources/continuous-safety-surveillance-for-medical-devices/index.html)

- May 5, 2026

### [Are patient outcomes getting lost in safety data complexity?](/content/resources/are-patient-outcomes-getting-lost-in-safety-data-complexity/index.html)

- May 5, 2026

[Previous: Future Ready Pharmacovigilance: When and Why to Outsource](/content/webinars/future-ready-pharmacovigilance-when-and-why-to-outsource/index.html)

[Next: Could GLP-1 obesity drugs break pharma’s safety infrastructure?](/content/resources/could-glp-1-obesity-drugs-break-pharmas-safety-infrastructure/index.html)